Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

Clinical Infectious Diseases

Volumn 39, Issue 10, 2004, Pages 1407-1416

  Van Burik, Jo Anne H ^a   Ratanatharathorn, Voravit ^b   Stepan, Daniel E ^c   Miller, Carole B ^d   Lipton, Jeffrey H ^f   Vesole, David H ^g   Bunin, Nancy ^h   Wall, Donna A ⁱ   Hiemenz, John W ^j   Satoi, Yoichi ^k   Lee, Jeanette M ^l   Walsh, Thomas J ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ Cardinal Glennon Hospital   (United States)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; MICAFUNGIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPOTENSION; HYPOTHESIS; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LIPOPROTEINS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC;

EID: 8744314133     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422312     Document Type: Article

References (21)

1. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
2. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
3. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
4. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331-40.
5. Van Burik J-A, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246-54.
6. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26:999-1004.
7. Walsh TJ. Echinocandins - an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002; 347:2070-2.
8. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001; 10:269-80.
9. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
10. Hatano K, Morishita Y, Nakai T, Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55:219-22.
11. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002; 48:78-81.
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
13. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982; 3:345-53.
14. Graybill JR. Hitting a new target with echinocandins: why chase something else? Curr Opin Investig Drugs 2001; 2:468-71.
15. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45:3322-7.
16. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14:685-91.
17. Nyfeler R, Keller-Schierlein W. Metabolites of microorganisms, 143: echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components [in German]. Helv Chim Acta 1974; 57:2459-77.
18. Sawistowska-Schroder ET, Kerridge D, Perry H. Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans. FEBS Lett 1984; 173:134-8.
19. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46:485-7.
20. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45:3310-21.
21. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.